Reassessing the cost-effectiveness of nivolumab for the treatment of renal cell carcinoma based on mature survival data, updated safety and lower comparator price-Reference-Cited by-同舟云学术

Reassessing the cost-effectiveness of nivolumab for the treatment of renal cell carcinoma based on mature survival data, updated safety and lower comparator price

Published:2021-01-01 Issue:1 Volume:24 Page:893-899
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Kim Hansoo¹^ORCID,Goodall Stephen²,Liew Danny¹

Affiliation:

1. School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia

2. Centre for Health Economics Research and Evaluation, University of Technology Sydney, Australia

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2021.1955540

Reference34 articles.

1. (AIHW), A.I.o.H.a.W. Cancer in Australia 2019. 2019; Available from: https://www.aihw.gov.au/reports/cancer/cancer-in-australia-2019/summary.

2. Surveillance, E., and End Results Program (SEER). SEER Stat Fact Sheets: Kidney and Renal Pelvis Cancer. 2020. Available from: https://seer.cancer.gov/statfacts/html/kidrp.html.

3. Current and future systemic treatments for renal cell carcinoma

4. Australia AGS. Pharmaceutical Benefits Schedule Item Reports. 2021. Available from: http://medicarestatistics.humanservices.gov.au/statistics/pbs_item.jsp.

5. (PBAC), A.P.B.A.C. Public Summary Document: Everolimus (RCC) March 2014. 2014; Available from: https://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/psd/2014-03/everolimus-rcc.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Scoping review of economic analyses of rare kidney diseases;Kidney International Reports;2024-09

2. Cost-effectiveness of abobotulinumtoxinA plus best supportive care compared with best supportive care alone for early treatment of adult lower limb spasticity following an acute event;PLOS ONE;2024-02-01

3. Cost-effectiveness of extracorporeal cardiopulmonary resuscitation for refractory out-of-hospital cardiac arrest: A modelling study;Resuscitation Plus;2022-12